Home > Products & Pipeline  |
Contact Us |
Glossary |
Site Map |
|
|
|||||
|
|
 |
|
|||
|
|
ABOUT VION | PRODUCTS & PIPELINE | CLINICAL TRIALS | INVESTOR RELATIONS |
|
|
|
 |
|
 Cloretazine® (VNP40101M) is a novel cytotoxic agent in clinical development for treatment of acute myelogenous leukemia (AML). In addition, clinical trials of Cloretazine® (VNP40101M) are underway in brain tumors in combination with temzolomide and in advanced hematologic malignancies in combination with hematopoietic cell transplantation. Triapine® is designed to prevent the replication of tumor cells by blocking DNA, an enzyme critical to synthesis and repair. Triapine® is in clinical trials sponsored by the National Cancer Institute.
|
|
| Privacy | Terms of Use | Copyright | ©2008 Vion Pharmaceuticals, Inc. |
|